ChemicalBook > Product Catalog >API >Synthetic Anti-infective Drugs >Anti-tuberculous mycobacterium leprae drugs >Ethambutol

Ethambutol

Ethambutol Structure
CAS No.
74-55-5
Chemical Name:
Ethambutol
Synonyms
emb;C06984;tibutol;MGC71745;diambutol;Etambutol;ETHAMBUTOL;d-ethambutol;Ethambutolum;Aethambutolum
CBNumber:
CB3324345
Molecular Formula:
C10H24N2O2
Molecular Weight:
204.31
MOL File:
74-55-5.mol
MSDS File:
SDS
Modify Date:
2024/7/2 8:55:06

Ethambutol Properties

Melting point 199-204℃
Boiling point 345℃
alpha D25 +13.7° (c = 2 in water)
Density 1.0048 (rough estimate)
refractive index 1.4610 (estimate)
RTECS EL3640000
Flash point >110°(230°F)
storage temp. Keep in dark place,Sealed in dry,2-8°C
solubility Soluble in DMSO
form Powder
pka pKa 6.6 (H2O) (Uncertain);9.5(H3O) (Uncertain)
color White to off-white
Water Solubility Soluble in water. Also soluble in chloroform and methylene chloride

SAFETY

Risk and Safety Statements

Symbol(GHS) 
GHS07
Signal word  Warning
Hazard statements  H302
Precautionary statements  P264-P270-P301+P312a-P330-P501a
Toxicity LD50 oral in rat: 998mg/kg

Ethambutol Chemical Properties,Uses,Production

Uses

Ethambutol is an antitubercular antibiotic.

Indications

Ethambutol is a water-soluble, heat-stable compound that acts by inhibition of arabinosyl transferase enzymes that are involved in cell wall biosynthesis. Nearly all strains of M. tuberculosis and M. kansasii and most strains of Mycobacterium avium-intracellulare are sensitive to ethambutol. Drug resistance relates to point mutations in the gene (EmbB) that encodes the arabinosyl transferases that are involved in mycobacterial cell wall synthesis.

Definition

ChEBI: An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial d ug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant str ins of M. tuberculosis are readily produced if ethambutol is used alone.

Antimicrobial activity

Ethambutol is active against several species of mycobacteria and nocardiae. MICs on solid media are: M. tuberculosis 0.5–2 mg/L; M. kansasii 1–4 mg/L; other slowly growing mycobacteria 2–8 mg/L; rapidly growing pathogens 2–16 mg/L; Nocardia spp. 8–32 mg/L.
Resistance is uncommon and is a multistep process due to mutations in the embA, embB and embC gene cluster. A mutation in codon 306 of the embB gene predisposes to the development of resistance to a range of antituberculosis agents, possibly by affecting cell-wall permeability.

Pharmaceutical Applications

A synthetic ethylenediamine derivative formulated as the dihydrochloride for oral administration. The dry powder is very soluble and stable.

Mechanism of action

The mechanism of action of EMB remains unknown, although mounting evidence suggests a specific site of action for EMB. It has been known for some time that EMB affects mycobacterial cell wall synthesis; however, the complicated nature of the mycobacterial cell wall has made pinpointing the site of action difficult. In addition to the peptidoglycan portion of the cell wall, the mycobacterium have a unique outer envelop consisting of arabinofuranose and galactose (AG), which is covalently attached to the peptidoglycan and an intercalated framework of lipoarabinomannan (LAM) . The AG portion of the cell wall is highly branched and contains distinct segments of galactan and distinct segments of arabinan. At various locations within the arabinan segments (terminal and penultimate), the mycolic acids are attached to the C-5′ position of arabinan. Initially, Takayama et al. reported that EMB inhibited the synthesis of the AG portion of the cell wall. More recently, it has been reported that EMB inhibits the enzymes arabinosyl transferase. One action of arabinosyl transferase is to catalyze the polymerization of D-arabinofuranose, leading to AG. Ethambutol mimics arabinan, resulting in a buildup of the arabinan precursor β-D-arabinofuranosyl- 1-monophosphoryldecaprenol and, as a result, a block of the synthesis of both AG and LAM. The mechanism of resistance to EMB involves a gene overexpression o

Pharmacology

Orally administered ethambutol is well absorbed (70–80%) from the gut, and peak serum concentrations are obtained within 2 to 4 hours of drug administration; it has a half-life of 3 to 4 hours. Ethambutol is widely distributed in all body fluids, including the cerebrospinal fluid, even in the absence of inflammation.A majority of the unchanged drug is excreted in the urine within 24 hours of ingestion. Up to 15% is excreted in the urine as an aldehyde and a dicarboxylic acid metabolite. Ethambutol doses may have to be modified in patients with renal failure.

Pharmacokinetics

Oral absorption: c. 80%, but some patients absorb it poorly
Cmax 25 mg/kg oral: 2–6 mg/L after 2–3 h
Plasma half-life: 10–15 h
Volume of distribution: >3 L/kg
Plasma protein binding: 20–30%
Absorption is impeded by aluminum hydroxide and alcohol. It is concentrated in the phagolysosomes of alveolar macrophages. It does not enter the cerebrospinal fluid (CSF) in health but CSF levels of 25–40% of the plasma concentration, with considerable variation between patients, are achieved in cases of tuberculous meningitis.
Various metabolites are produced, including dialdehyde, dicarboxylic acid and glucuronide derivatives. Around 50% is excreted unchanged in the urine, with an additional 10–15% as metabolites, and 20% is excreted unchanged in feces.

Clinical Use

Ethambutol has replaced aminosalicylic acid as a first-line antitubercular drug. It is commonly included as a fourth drug, along with isoniazid, pyrazinamide, and rifampin, in patients infected with MDR strains. It also is used in combination in the treatment of M. aviumintracellulare infection in AIDS patients.

Side effects

The major toxicity associated with ethambutol use is retrobulbar neuritis impairing visual acuity and redgreen color discrimination; this side effect is dose related and reverses slowly once the drug is discontinued. Mild GI intolerance, allergic reaction, fever, dizziness, and mental confusion are also possible. Hyperuricemia is associated with ethambutol use due to a decreased renal excretion of urates; gouty arthritis may result.

Global( 110)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
CLEARSYNTH LABS LTD. +91-22-45045900 Hyderabad, India 6351 58 Inquiry
Triveni chemicals 08048762458 New Delhi, India 6093 58 Inquiry
Pharmaffiliates Analytics and Synthetics P. Ltd +91-172-5066494 Haryana, India 6773 58 Inquiry
Pharma Affiliates 172-5066494 Haryana, India 6761 58 Inquiry
Shaanxi TNJONE Pharmaceutical Co., Ltd +8618740459177 China 1142 58 Inquiry
.GZ HONESTCHEM CO.,LTD +86-15013270415 China 246 58 Inquiry
Xiamen AmoyChem Co., Ltd +86-592-6051114 +8618959220845 China 6387 58 Inquiry
career henan chemical co +86-0371-86658258 +8613203830695 China 29826 58 Inquiry
Hefei TNJ Chemical Industry Co.,Ltd. 0551-65418671 China 34571 58 Inquiry
Dideu Industries Group Limited +86-29-89586680 +86-15129568250 China 26114 58 Inquiry

Related articles

  • Side-effects of Ethambutol
  • Ethambutol was discovered at Lederle Laboratories in 1961, when randomly selected synthetic compounds were being tested for an....
  • Mar 25,2022
ETHAMBUTOL (+)-2,2-(Ethylenediimino)di-1-butanol (+)-2,2’-(ethylenediimino)di-1-butanol (+)-n,n’-bis(1-(hydroxymethyl)propyl)ethylenediamine (+)-s,s-ethambutol (r)-2,2’-(1,2-ethanediyldiimino)bis-1-butanol 2,2’-(1,2-ethanediyldiimino)bis-,(r-(r*,r*))-1-butano 2’-(1,2-ethanediyldiimino)bis-(r)-1-butano 2’-(ethylenediimino)di-(+)-1-butano d,n,n’-bis(1-hydroxymethylpropyl)ethylenediamine d-2,2’-(ethylenediimino)bis(1-butanol) d-2,2’-(ethylenediimino)di-1-butanol d-ethambutol diambutol d-n,n’-bis(1-hydroxymethylpropyl)ethylenediamine tibutol (+)-2,2-ethylenediiminodibutan-1-ol ETHAMBUTOL FREE BASE Ethambutol HCL BP98,CP2000 Ethambutol BP98 ETHAMBUTOL HCL, USP STANDARD 2,2(1,2-Ethanediyldiimino)-bis-1-butanol (2S,7S)-2,7-Diethyl-3,6-diazaoctane-1,8-diol 1-Butanol, 2,2'-(1,2-ethanediyldiimino)bis-, (2S,2'S)- 1-Butanol, 2,2'-(1,2-ethanediyldiimino)bis-, [S-(R*,R*)]- Etambutol 2'-(1,2-ethanediyldiimino)bis-(r)-1-butanol Ethambutol (base and/or unspecified salts) (3-Oxo-1-butynyl)benzene 4-Phenyl-3-butyne-2-one Acetylphenylacetylene Methyl phenylethynyl ketone Phenylethynyl methyl ketone 2,2'-(1,2-Ethanediyldiimino)bis[(2S)-1-butanol] C06984 (+)- (R,R)-NN'-Ethylene bis(2-aMinobutan-1-ol) EthaMbutol API (2S,2'S)-2,2'-(Ethane-1,2-diylbis(azanediyl))bis(butan-1-ol) Anti-Embigin precursor Anti-EMB antibody produced in rabbit MGC71745 Ethambutol USP/EP/BP emb Aethambutolum Ethambutolum 74-55-5